Guangzhou's high-tech enterprises are making significant strides on the global stage, showcasing their innovative prowess and strategic foresight.
Akeso has announced that its PD-1/VEGF dual antibody, Ivonescimab, which is under clinical research, has shown significant advantages over "Keytruda", becoming the world's first drug to demonstrate such effectiveness.
More than twenty years ago, Amway conducted a nationwide factory site selection survey and eventually settled in the Guangzhou Development District (GDD), deeply integrating into the Chinese market.
The leading domestic enterprise in Organic Photovoltaics (OPV), Guangzhou Chasing Light Technology Company, recently signed an agreement to settle in the Kaitou Zhixing Industrial Space in the Huangpu district and Guangzhou High-Tech District.
Guangzhou International Bio Island recently hosted the "Cross-Border Medical Technology CEOs Guangzhou Tour" exchange activity in the Huangpu district.
On Sept 12, Guangzhou SupBio Bio-Technology and Science Company held a product launch event at the Huangpu International Talent Lounge.
Recently, at the inaugural AI Discovery Summit 2024 in Huangpu district, iSoftStone announced the establishment of iSoftStone Intelligent Computing Headquarters in Huangpu and the release of various full-stack intelligent products.
The list of outstanding cases for 2024's inaugural Small and Beautiful International Mutual Recognition Cooperation in Quality Certification was recently released.
China Pacific Insurance Guangzhou Branch recently partnered with the Innovation Center of High-Performance Medical Devices to launch Guangzhou's first biomedical technology insurance.
Carl Zeiss Vision (China) Company in Guangzhou Development District (GDD), founded by the Zeiss Group in 1995, is quickly emerging as a significant representative of the physical economy in GDD.